The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Does postoperative cfDNA affect MRD detection rates in CRC?
Stacey Cohen, MD, Fred Hutchinson Cancer Center, Seattle, WA, discusses the impact of cell-free DNA (cfDNA) levels post-surgery on minimal residual disease (MRD) detection rates in patients with stage I-III colorectal cancer (CRC). A real-world analysis analyzed over 14,000 patients who had CRC and underwent surgery. In a cohort of 450 patients who had a known date of surgery, cfDNA decreases two weeks after surgery, and did not affect circulating tumor DNA (ctDNA) detection. Ultimately, these findings suggest MRD testing can occur two weeks after surgery. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
